IL217833A0 - Inhibitors of cognitive decline - Google Patents

Inhibitors of cognitive decline

Info

Publication number
IL217833A0
IL217833A0 IL217833A IL21783312A IL217833A0 IL 217833 A0 IL217833 A0 IL 217833A0 IL 217833 A IL217833 A IL 217833A IL 21783312 A IL21783312 A IL 21783312A IL 217833 A0 IL217833 A0 IL 217833A0
Authority
IL
Israel
Prior art keywords
inhibitors
cognitive decline
cognitive
decline
Prior art date
Application number
IL217833A
Other languages
English (en)
Original Assignee
Cognition Therapeutics Inc
Rishton Gilbert M
Catalano Susan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc, Rishton Gilbert M, Catalano Susan filed Critical Cognition Therapeutics Inc
Publication of IL217833A0 publication Critical patent/IL217833A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/25Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/28Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
    • C07C33/30Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/18Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL217833A 2009-07-31 2012-01-30 Inhibitors of cognitive decline IL217833A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23032609P 2009-07-31 2009-07-31
US30868610P 2010-02-26 2010-02-26
PCT/US2010/044136 WO2011014880A1 (en) 2009-07-31 2010-08-02 Inhibitors of cognitive decline

Publications (1)

Publication Number Publication Date
IL217833A0 true IL217833A0 (en) 2012-03-29

Family

ID=43529740

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217833A IL217833A0 (en) 2009-07-31 2012-01-30 Inhibitors of cognitive decline

Country Status (12)

Country Link
US (2) US9192585B2 (OSRAM)
EP (1) EP2458983B1 (OSRAM)
JP (1) JP2013501006A (OSRAM)
CN (1) CN102595884B (OSRAM)
AU (2) AU2010278711A1 (OSRAM)
BR (1) BR112012002246A2 (OSRAM)
DK (1) DK2458983T3 (OSRAM)
ES (1) ES2547730T3 (OSRAM)
IL (1) IL217833A0 (OSRAM)
RU (1) RU2012107457A (OSRAM)
SG (2) SG10201506978UA (OSRAM)
WO (1) WO2011014880A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2416795T3 (en) 2009-04-09 2015-08-31 Cognition Therapeutics Inc INHIBITORS OF cognitive decline
SG10201506978UA (en) 2009-07-31 2015-10-29 Cognition Therapeutics Inc Inhibitors Of Cognitive Decline
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
EP2670402B1 (en) * 2011-02-02 2017-09-20 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
BR112013023705B8 (pt) * 2011-03-29 2020-01-28 Council Scient Ind Res processo para a modificação de óleo essencial de curcuma aromatica
GB201111319D0 (en) * 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
US20170197977A9 (en) * 2011-08-25 2017-07-13 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
CA2846611A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
JP6517827B2 (ja) * 2014-01-31 2019-05-22 コグニション セラピューティクス,インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
JPS59155343A (ja) 1983-01-31 1984-09-04 イーライ・リリー・アンド・カンパニー 動物の改良飼育法
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
CN1312116C (zh) 1994-10-21 2007-04-25 Nps药物有限公司 钙受体活性化合物
JP3522930B2 (ja) * 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
EP0915888A1 (en) 1996-04-24 1999-05-19 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) * 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
CA2473874C (en) 2001-12-14 2011-11-22 Council Of Scientific And Industrial Research A composition for treating neurocerebrovascular disorders
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
MXPA06010384A (es) 2004-03-12 2007-03-07 Egis Gyogyszergyar Nyrt Composicion farmaceutica combinada para la inhibicion de la declinacion de las funciones congnoscitivas.
TW200538052A (en) * 2004-05-31 2005-12-01 Kaneka Corp Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component
AU2005253776B8 (en) 2004-06-21 2012-02-02 King's College London Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
BRPI0608076A2 (pt) 2005-03-05 2009-11-10 Abbott Gmbh & Co Kg método de seleção, processo para purificação de oligÈmeros beta-a não difusìveis, anticorpos seletivos contra os ditos oligÈmeros beta-a não difusìveis e um processo para fabricação dos ditos anticorpos
EP1896005A4 (en) 2005-06-15 2009-11-11 Darrick S H L Kim SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
JP2009530305A (ja) * 2006-03-17 2009-08-27 ハーバルサイエンス シンガポール ピーティーイー. リミテッド ウコン種を含む抽出物および方法
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
JP2010527375A (ja) 2007-05-15 2010-08-12 ヘリコン セラピューティクス,インコーポレイテッド Gpr12の阻害による認知障害の治療方法
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
WO2009059214A1 (en) 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
EP2138104A1 (en) 2008-06-25 2009-12-30 Vibra Tech AB Core biopsy arrangement
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
ES2638779T3 (es) 2009-03-16 2017-10-24 Pangu Biopharma Limited Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
DK2416795T3 (en) 2009-04-09 2015-08-31 Cognition Therapeutics Inc INHIBITORS OF cognitive decline
SG10201506978UA (en) 2009-07-31 2015-10-29 Cognition Therapeutics Inc Inhibitors Of Cognitive Decline
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
US20170197977A9 (en) 2011-08-25 2017-07-13 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease

Also Published As

Publication number Publication date
CN102595884B (zh) 2014-12-03
US9192585B2 (en) 2015-11-24
SG10201506978UA (en) 2015-10-29
SG178191A1 (en) 2012-03-29
DK2458983T3 (en) 2015-10-05
BR112012002246A2 (pt) 2019-09-24
AU2010278711A1 (en) 2012-02-23
US20160137588A1 (en) 2016-05-19
US20120129945A1 (en) 2012-05-24
ES2547730T3 (es) 2015-10-08
EP2458983A4 (en) 2012-12-19
EP2458983B1 (en) 2015-07-08
AU2015242947A1 (en) 2015-10-29
RU2012107457A (ru) 2013-09-10
EP2458983A1 (en) 2012-06-06
AU2015242947B2 (en) 2017-09-28
JP2013501006A (ja) 2013-01-10
HK1171624A1 (en) 2013-04-05
WO2011014880A1 (en) 2011-02-03
US9815770B2 (en) 2017-11-14
CN102595884A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
ZA201700326B (en) Inhibitors of beta-secretase
EP2440054A4 (en) PYRIDILTRIA INHIBITOR OF HEDGEHOG SIGNALING
IL215645A0 (en) Inhibitors of cognitive decline
ZA201206424B (en) Inhibitors of semicarabazide-sensitive amine oxidase
ZA201203289B (en) Use of bethanechol for treatment of zerostomia
PL2521746T3 (pl) Hamowanie utleniania amin
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
IL217833A0 (en) Inhibitors of cognitive decline
ZA201206456B (en) Uses of dgati inhibitors
EP2438246A4 (en) CONSTRUCTION ASPECTS
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
GB0915515D0 (en) Treatment of vasculoproliferative conditions
SMT202100234T1 (it) Usi di inibitori di fattori inducibili da ipossia
PT2440558E (pt) Compostos de dihidropirrolonaftirridinona como inibidores de jak
IL220153A0 (en) Inhibitors of akt activity
PL2493496T3 (pl) Zastosowanie GSTP1
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
IL217756A0 (en) Inhibitors of jnk
PT2411376E (pt) Inibidores de nf-kb
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0903651D0 (en) Inhibitors of glyoxalase
GB0905098D0 (en) Use of biomarkers
GB0905280D0 (en) Novel uses of VEGFxxxb